

THE COMPARATIVE EFFECTIVENESS OF ANTI-TNF IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

Triana Lobaton

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A retrospective Belgian study of 114 IBD patients found that overall effectiveness of anti-TNF therapy did not differ significantly between bio-naïve and bio-experienced patients, though some specific outcome measures favored bio-naïve patients at certain time points.

KEY POINTS

- After induction, bio-naïve patients had significantly higher biochemical response (87.8% vs. 68.6%, $P=0.021$) and biochemical remission (87.8% vs. 64.7%, $P=0.007$), with Crohn's disease patients showing higher rates than ulcerative colitis patients on multivariate analysis.
- At one year, significantly more bio-naïve patients achieved clinical remission (78.2% vs. 60.4%, $P=0.045$) and endoscopic response (81.3% vs. 54.1%, $P=0.017$), though these differences did not remain significant after multivariate adjustment.
- Clinical response and remission after induction, and endoscopic remission at one year, showed no significant differences between bio-naïve and bio-experienced groups.
- Treatment survival showed no significant difference between bio-naïve and bio-experienced patients (aHR 1.54, $P=0.273$) on Cox regression analysis.
- Bio-experienced patients had significantly more comorbidities and longer disease duration at baseline, which may inform interpretation of comparative outcomes.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/7581c0ca-743c-11ee-a08c-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.